Predictive factors for hematological ORR
| . | Nonresponders (n = 18) . | Responders (n = 22) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 69 (68-72) | 69 (62-75) | .92 |
| Male sex | 10 (55.6) | 15 (68.2) | .52 |
| No previous lines of treatment, median (IQR) | 2 (1.25-3) | 3 (2-3) | .50 |
| Refractory/poor AL responders | 13 (72.2) | 9 (40.9) | .062 |
| Light chain λ | 15 (83.3) | 15 (68.2) | .46 |
| Light chain only | 7 (38.9) | 11 (50.0) | .54 |
| ECOG performance status | |||
| 0 | 8 (44.4) | 6 (27.3) | .33 |
| 1 | 7 (38.9) | 14 (63.6) | |
| 2 | 3 (16.7) | 2 (9.1) | |
| Bone marrow PCs, median % (IQR) | 3.0 (1.3-6.5) | 3.0 (1.0-5.0) | .61 |
| dFLC at baseline, median (IQR) | 169 (112-308) | 145 (115-336) | .88 |
| dFLC <180 mg/L | 10 (55.6) | 13 (59.0) | 1.00 |
| dFLC after 1 injection, median (IQR), mg/L | 137 (82-238) | 38 (26-69) | <.001 |
| dFLC decrease after 1 injection, % | 24 | 63 | <.001 |
| . | Nonresponders (n = 18) . | Responders (n = 22) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 69 (68-72) | 69 (62-75) | .92 |
| Male sex | 10 (55.6) | 15 (68.2) | .52 |
| No previous lines of treatment, median (IQR) | 2 (1.25-3) | 3 (2-3) | .50 |
| Refractory/poor AL responders | 13 (72.2) | 9 (40.9) | .062 |
| Light chain λ | 15 (83.3) | 15 (68.2) | .46 |
| Light chain only | 7 (38.9) | 11 (50.0) | .54 |
| ECOG performance status | |||
| 0 | 8 (44.4) | 6 (27.3) | .33 |
| 1 | 7 (38.9) | 14 (63.6) | |
| 2 | 3 (16.7) | 2 (9.1) | |
| Bone marrow PCs, median % (IQR) | 3.0 (1.3-6.5) | 3.0 (1.0-5.0) | .61 |
| dFLC at baseline, median (IQR) | 169 (112-308) | 145 (115-336) | .88 |
| dFLC <180 mg/L | 10 (55.6) | 13 (59.0) | 1.00 |
| dFLC after 1 injection, median (IQR), mg/L | 137 (82-238) | 38 (26-69) | <.001 |
| dFLC decrease after 1 injection, % | 24 | 63 | <.001 |
All data are n (%), unless otherwise indicated.
ECOG, Eastern Cooperative Oncology Group.